News BI strikes billion-dollar cancer immunotherapy deal with OSE Could BI be looking to develop combination therapy?
News Pfizer's lung cancer drug dacomitinib gets fast US review Drug beat AZ's Iressa in head-to-head trial, concerns over side-effects
Oncology Celgene's COO quits after troubles with new drugs Celgene’s chief operating officer and inflammatory diseases guru Scott Smith has quit the company, in the aftermath of the FDA’s rejection of a key multiple sclerosis pill, and a late-stage
News Ex-Kite chiefs' biotech to research 'off-the-shelf' CAR-Ts w... Belldegrun and Chang's Allogene to take over from Pfizer in R&D deal
News Gilead strikes again, penning $5bn deal to buy Tubulis Gilead has signed its third acquisition deal since the start of the year, agreeing to buy ADC specialist Tubulis for $3.15bn upfront.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
